Evidence map›Paper›PMID 35782688›Full record

ArticlePharmacogenomics and personalized medicine2022

Impact of

Yomna M El-Meligui, Naglaa M Hassan, Amira B Kassem, Nora A Gouda, Marwa Mohanad, Manal A Hamouda, Ahmad Salahuddin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yomna M El-MeliguiClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0001-6848-5743
Naglaa M HassanClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0002-3195-1568
Amira B KassemClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.ORCID 0000-0003-4195-6036
Nora A GoudaCancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Marwa MohanadBiochemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt.
Manal A HamoudaClinical Pharmacy Department, Faculty of Pharmacy, Menoufia University, Shibin El Kom, Egypt.
Ahmad SalahuddinBiochemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.ORCID 0000-0002-7382-4284
Cairo University · EGDamanhour University · EGMenoufia University · EGMisr University for Science and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acute myeloid leukemia (AML) is the most common type of leukemia among adults and is characterized by various genetic abnormalities. Methods: This study included 83 de novo AML adult patients. All patients were subjected to clinical, morphological, cytochemical, and molecular analysis to detect Results: The results showed that a low expression of Conclusion: Further larger study should be conducted to verify that high

Indexed as

AMLFLT3-ITDHOXB4NPM1 exon 12PRDM16

Identifiers

PMID35782688
PMCPMC9241994
OpenAlexW4283461058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.